Published in Clin Cancer Res on January 01, 2005
The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer (2011) 3.42
Migrastatin analogues target fascin to block tumour metastasis. Nature (2010) 2.84
Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer (2006) 1.62
Filopodia and adhesion in cancer cell motility. Cell Adh Migr (2011) 1.48
Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell (2007) 1.45
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res (2006) 1.45
Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J Clin Invest (2014) 1.33
Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem (2007) 1.30
Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J Clin Pathol (2006) 1.25
Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer (2012) 1.20
Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One (2011) 1.10
Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med (2013) 1.09
Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer (2007) 1.04
Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer (2006) 1.03
Fascin-1 promoter activity is regulated by CREB and the aryl hydrocarbon receptor in human carcinoma cells. PLoS One (2009) 1.01
Fascin protein is critical for transforming growth factor β protein-induced invasion and filopodia formation in spindle-shaped tumor cells. J Biol Chem (2011) 1.00
Molecular mechanism of fascin function in filopodial formation. J Biol Chem (2012) 0.99
Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics. Genes Cancer (2010) 0.98
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics (2009) 0.94
Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics (2013) 0.91
GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion. J Biol Chem (2013) 0.91
Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity. BMC Cancer (2008) 0.88
Fascin expression in colorectal carcinomas. Clinics (Sao Paulo) (2010) 0.88
CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy. J Mol Histol (2013) 0.87
Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas. Clin Exp Metastasis (2012) 0.87
Drosophila Fascin is a novel downstream target of prostaglandin signaling during actin remodeling. Mol Biol Cell (2012) 0.86
Biomarkers for Basal-like Breast Cancer. Cancers (Basel) (2010) 0.86
Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery. J Proteome Res (2009) 0.85
Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int J Oncol (2013) 0.84
Expression of fascin in thyroid neoplasms: a novel diagnostic marker. J Cancer Res Clin Oncol (2008) 0.83
Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth (2012) 0.82
Fascin promotes the motility and invasiveness of pancreatic cancer cells. World J Gastroenterol (2011) 0.81
Prostaglandins regulate nuclear localization of Fascin and its function in nucleolar architecture. Mol Biol Cell (2015) 0.81
Targeted inhibition of fascin function blocks tumour invasion and metastatic colonization. Nat Commun (2015) 0.81
A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions. Dis Model Mech (2012) 0.80
miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am J Transl Res (2016) 0.79
Myosin-X and disease. Exp Cell Res (2015) 0.79
Fascin upregulation in primary head and neck squamous cell carcinoma is associated with lymphatic metastasis. Oncol Lett (2014) 0.79
Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. J Med Chem (2014) 0.78
[Improvement of breast cancer grading in punch biopsies: grading with the Ki-67 marker]. Pathologe (2006) 0.77
Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women. Diagn Pathol (2014) 0.77
Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer. Virchows Arch (2015) 0.77
Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncol Lett (2015) 0.77
Regulation and functional significance of CDC42 alternative splicing in ovarian cancer. Oncotarget (2015) 0.76
Monoubiquitination Inhibits the Actin Bundling Activity of Fascin. J Biol Chem (2016) 0.75
Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2. Sci Rep (2016) 0.75
Expression of Fascin-1 on human lung cancer and paracarcinoma tissue and its relation to clinicopathological characteristics in patients with lung cancer. Onco Targets Ther (2015) 0.75
Immunohistochemical analysis of oral dysplasia: diagnostic assessment by fascin and podoplanin expression. Acta Histochem Cytochem (2011) 0.75
XIAP 3'-untranslated region as a ceRNA promotes FSCN1 function in inducing the progression of breast cancer by binding endogenous miR-29a-5p. Oncotarget (2017) 0.75
Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med (2016) 0.75
Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank. Biomark Cancer (2017) 0.75
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol (2011) 4.70
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 3.59
Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med (2007) 3.55
Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces. FASEB J (2002) 3.45
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest (2003) 3.14
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med (2009) 2.97
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) (2010) 2.57
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol (2005) 2.39
Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol (2007) 2.24
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol (2007) 2.15
Molecular phylogeny of the kelch-repeat superfamily reveals an expansion of BTB/kelch proteins in animals. BMC Bioinformatics (2003) 2.10
Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. Leuk Lymphoma (2015) 2.09
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol (2014) 1.97
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol (2008) 1.95
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (2013) 1.91
Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol (2006) 1.90
Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol (2002) 1.87
Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol (2003) 1.80
A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology (2006) 1.80
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood (2014) 1.71
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol (2006) 1.70
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol (2008) 1.69
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat (2008) 1.68
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res (2011) 1.67
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood (2014) 1.66
Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer (2006) 1.62
Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J (2004) 1.62
Laparoscopic anatrophic nephrolithotomy: feasibility study in a chronic porcine model. J Urol (2003) 1.58
Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells. Am J Pathol (2007) 1.46
Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol (2008) 1.46
Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell (2007) 1.45
Interaction of fascin and protein kinase Calpha: a novel intersection in cell adhesion and motility. EMBO J (2003) 1.45
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res (2006) 1.45
Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol (2009) 1.43
BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum (2012) 1.42
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst (2012) 1.42
HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Ann Surg Oncol (2008) 1.41
The evolution of extracellular matrix. Mol Biol Cell (2010) 1.40
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol (2012) 1.40
Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol (2005) 1.38
Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl Immunohistochem Mol Morphol (2003) 1.37
Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol (2007) 1.36
The roles of fascins in health and disease. J Pathol (2011) 1.35
Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem (2008) 1.30
ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn (2013) 1.30
Malignant solitary fibrous tumor: report of 3 cases with unusual features. Appl Immunohistochem Mol Morphol (2009) 1.26
Defining the expression pattern of the LGI1 gene in BAC transgenic mice. Mamm Genome (2007) 1.25
Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat (2006) 1.20
Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol (2005) 1.19
The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study. Arch Pathol Lab Med (2006) 1.19
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res (2012) 1.19
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn (2008) 1.17
Novel role of the muskelin-RanBP9 complex as a nucleocytoplasmic mediator of cell morphology regulation. J Cell Biol (2008) 1.15
Expression of fascin-1, the gene encoding the actin-bundling protein fascin-1, during mouse embryogenesis. Gene Expr Patterns (2004) 1.14
Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol (2009) 1.14
The evolution of thrombospondins and their ligand-binding activities. Mol Biol Evol (2010) 1.12
Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol (2007) 1.10
Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med (2013) 1.09
Comparative genomics of the syndecans defines an ancestral genomic context associated with matrilins in vertebrates. BMC Genomics (2006) 1.07
The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol (2005) 1.05
Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med (2006) 1.04
Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. Am J Surg Pathol (2007) 1.04
Variation of monosomy 3 status within uveal melanoma. Arch Pathol Lab Med (2009) 1.04
HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol (2002) 1.04
Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma. Diagn Mol Pathol (2003) 1.04
Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol (2007) 1.04
Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood (2012) 1.03
Prediction and analysis of higher-order coiled-coils: insights from proteins of the extracellular matrix, tenascins and thrombospondins. Int J Biochem Cell Biol (2013) 1.03
Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer (2007) 1.03
Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res (2011) 1.02
Rac regulates the interaction of fascin with protein kinase C in cell migration. J Cell Sci (2008) 1.01
Trimeric assembly of the C-terminal region of thrombospondin-1 or thrombospondin-2 is necessary for cell spreading and fascin spike organisation. J Cell Sci (2002) 1.01